<p>Kodiak Sciences（纳斯达克股票代码：KOD - 获取免费报告）于周四发布了季度财报。公司报告本季度每股收益（EPS）为（$0.84），超出市场共识预期的（$0.90）$0.06，Zacks 报道。</p>
<p>获取 <strong>Kodiak Sciences</strong> 的提醒：</p>
<h2>Kodiak Sciences 股票表现</h2>
<p>纳斯达克：KOD 周五开盘价为 $3.06。该股票的 50 日简单移动平均线为 $4.93，200 日简单移动平均线为 $5.40。Kodiak Sciences 的 52 周最低价为 $2.19，52 周最高价为 $11.60。公司的市值为 $1.6103 亿，市盈率为 -0.84，贝塔系数为 2.26。</p>
<h2>华尔街分析师观点</h2>
<p>另外，杰富瑞金融集团在 12 月 9 日的研究报告中将 Kodiak Sciences 的股票评级从 “持有” 上调至 “买入”，并设定了 $20.00 的目标价。</p>
<p><strong>阅读我们关于 KOD 的最新股票报告</strong></p>
<h2>Kodiak Sciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Kodiak Sciences Inc 是一家临床阶段的生物制药公司，研究、开发和商业化治疗视网膜疾病的疗法。其主要产品候选药物是 tarcocimab tedromer（KSI-301），这是一种抗血管内皮生长因子抗体生物聚合物，目前正在进行治疗湿性年龄相关性黄斑变性（AMD）的 IIb/III 期临床研究，以及用于治疗糖尿病性黄斑水肿、因视网膜静脉阻塞引起的初发性黄斑水肿和非增殖性糖尿病视网膜病变的 III 期临床研究。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Kodiak Sciences</li>
<li>什么是股息？购买最佳股息股票</li>
<li>便士股票激增 70%：买入的一个理由，卖出的五个理由</li>
<li>什么是空头头寸？如何使用它</li>
<li>三大饮料股票带来丰厚利润</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E"/></p>
<h2>你现在应该投资 $1,000 在 Kodiak Sciences 吗？</h2>
<p>在你考虑 Kodiak Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Kodiak Sciences 并不在名单上。</p>
<p>虽然 Kodiak Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Kodiak Sciences（纳斯达克代码：KOD）报告的季度每股收益为（$0.84），超出分析师预期的（$0.87）$0.03。该股票开盘价为$3.06，市值为 1.6103 亿美元。杰富瑞金融集团将 Kodiak Sciences 的评级从 “持有” 上调至 “买入”，目标价为$20.00。该公司专注于开发视网膜疾病的治疗药物，其主要产品候选药物正在进行高级临床研究</p>

<p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.06, Zacks reports.</p>
<div class="lb-trans"><p>Kodiak Sciences（纳斯达克股票代码：KOD - 获取免费报告）于周四发布了季度财报。公司报告本季度每股收益（EPS）为（$0.84），超出市场共识预期的（$0.90）$0.06，Zacks 报道。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kodiak Sciences</strong> 的提醒：</p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表现</h2>
</div><p>NASDAQ:KOD opened at $3.06 on Friday. The stock has a 50-day simple moving average of $4.93 and a 200 day simple moving average of $5.40. Kodiak Sciences has a 52-week low of $2.19 and a 52-week high of $11.60. The company has a market cap of $161.03 million, a PE ratio of -0.84 and a beta of 2.26.</p>
<div class="lb-trans"><p>纳斯达克：KOD 周五开盘价为 $3.06。该股票的 50 日简单移动平均线为 $4.93，200 日简单移动平均线为 $5.40。Kodiak Sciences 的 52 周最低价为 $2.19，52 周最高价为 $11.60。公司的市值为 $1.6103 亿，市盈率为 -0.84，贝塔系数为 2.26。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $20.00 target price on the stock in a research note on Monday, December 9th.</p>
<div class="lb-trans"><p>另外，杰富瑞金融集团在 12 月 9 日的研究报告中将 Kodiak Sciences 的股票评级从 “持有” 上调至 “买入”，并设定了 $20.00 的目标价。</p>
</div><p><strong>Read Our Latest Stock Report on KOD</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 KOD 的最新股票报告</strong></p>
</div><h2>Kodiak Sciences Company Profile</h2>
<div class="lb-trans"><h2>Kodiak Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc 是一家临床阶段的生物制药公司，研究、开发和商业化治疗视网膜疾病的疗法。其主要产品候选药物是 tarcocimab tedromer（KSI-301），这是一种抗血管内皮生长因子抗体生物聚合物，目前正在进行治疗湿性年龄相关性黄斑变性（AMD）的 IIb/III 期临床研究，以及用于治疗糖尿病性黄斑水肿、因视网膜静脉阻塞引起的初发性黄斑水肿和非增殖性糖尿病视网膜病变的 III 期临床研究。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell</li>
<li>What is Short Interest? How to Use It</li>
<li>Top 3 Beverage Stocks Pouring Out Profits</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>CarMax and Carvana: Steering the Used Car Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Kodiak Sciences</li>
<li>什么是股息？购买最佳股息股票</li>
<li>便士股票激增 70%：买入的一个理由，卖出的五个理由</li>
<li>什么是空头头寸？如何使用它</li>
<li>三大饮料股票带来丰厚利润</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>CarMax 和 Carvana：引领二手车市场</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=KOD"/></p>
<h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Kodiak Sciences 吗？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Kodiak Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Kodiak Sciences 并不在名单上。</p>
</div><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kodiak Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kodiak Sciences（纳斯达克股票代码：KOD）公布收益结果，每股收益超出预期 0.06 美元